close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Rubella no longer major problem in U.S.

Breaking News -- March 21, 2005

CDC says rubella no longer a major public health threat in the U.S.

WASHINGTON, D.C., March 21, 2005 -- A major public health milestone has been achieved -- the rubella virus, a major cause of serious birth defects such as deafness and blindness, also known as congenital rubella syndrome (CRS), is no longer considered to be a major public health threat in the United States, Dr. Julie Gerberding, director, Centers for Disease Control and Prevention announced at the National Immunization Conference in Washington, DC.

"The elimination of rubella in the United States is a tremendous step in protecting the health and well being of pregnant women and infants," said Dr. Gerberding. "A disease that once seriously harmed tens of thousands of infants is no longer a major health threat, thanks to a safe and effective vaccine and successful immunization programs across the country. We should take pride in this accomplishment, and also recognize that we must maintain our vigilance or we can see a resurgence of disease."

Currently about 93 percent of the nation's children under age two are vaccinated against measles, mumps and rubella, according to the CDC's National Immunization Survey. More than 95 percent of the nation's children are vaccinated against rubella by the time they enter school. "The importance of continuing vaccination cannot be emphasized enough," said Dr. Steve Cochi, Acting Director, CDC's National Immunization Program. "Cases of rubella continue to be brought into the country by worldwide travelers and because of bordering countries where the disease is active."

During 1964 and 1965 a rubella epidemic in the United States caused an estimated 12.5 million cases of rubella and 20,000 cases of congenital rubella syndrome (CRS) which led to more than 11,600 babies born deaf, 11,250 fetal deaths, 2,100 neonatal deaths, 3,580 babies born blind and 1,800 babies born mentally retarded.

Since reporting of rubella began in 1966, the largest number of rubella cases reported was in 1969 with 57,686 cases. Following vaccine licensure in 1969 and development of a rubella vaccination program to prevent rubella infection during pregnancy, rubella incidence fell rapidly. By 1983, fewer than 1,000 cases were reported per year.

In 1989, CDC established a rubella elimination goal despite a resurgence in rubella and measles cases during the measles epidemic from 1989-1991, reported rubella cases in the 1990s declined to all-time low numbers. From 1990 through 1999, only 117 cases of CRS were reported, 66 of these babies were born in 1990 and 1991. In 2001, for the first time in history, less than 100 cases were reported in the United States. In 2003, there were only eight rubella cases and one CRS case reported in the United States. In 2004, there were only nine rubella cases reported in the United States.

Since the mid-1990s, the United States has worked closely with the Pan American Health Organization (PAHO) and Mexico to improve rubella control in the Americas. Those efforts have resulted in dramatic reductions of rubella in many nations of the Americas. In September 2003, ministers of health of all countries in the Americas resolved to eliminate rubella and CRS by 2010.

Last fall, an independent panel including internationally recognized immunization experts from academia, the Council for State and Territorial Epidemiologists (CSTE), the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the Pan American Health Organization (PAHO), Mexico and the CDC concluded that rubella virus in no longer endemic in the United States.

Rubella is prevented through vaccination. Rubella vaccine is recommended for all children and for adolescents and adults without documented evidence of immunity. It is especially important to verify that all women of child-bearing age are immune to rubella before they get pregnant.

Although it is available as a single preparation, it is recommended that rubella vaccine be given as MMR vaccine (protecting against measles, mumps and rubella). The first dose of MMR should be given on or after the first birthday; the recommended range is from 12-15 months. The second dose is usually given when the child is 4-6 years old, or before he or she enters kindergarten or first grade. Maintaining high coverage and rubella population immunity in the United States among children and adults will be important to maintain the benefits of achieving rubella elimination.

Source: CDC press release

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...